|Videos|April 8, 2021
Somatic and Germline Testing in Advanced Ovarian Cancer
Author(s)Rebecca Previs, MD
Dr. Rebecca Previs explains the importance of somatic and germline testing in guiding first line treatment selection in women with advanced ovarian cancer.
Advertisement
Advertisement
Related to this article
New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.
Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.
Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
4
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
5